Frontiers in CNS Drug Discovery

Volume: 1

Indexed in: Scopus, EMBASE, Book Citation Index, Science Edition, BIOSIS

“Frontiers in CNS Drug Discovery” is an eBook series devoted to publishing the latest and the most important advances in Central Nervous System (CNS) drug design and discovery. Eminent scientists ...
[view complete introduction]

US $
15

*(Excluding Mailing and Handling)



The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in CNS Disorders

Pp. 390-399 (10)

Rafael Roesler, Flavio Kapczinski, Joao Quevedo, Felipe Dal Pizzol and Gilberto Schwartsmann

Abstract

Gastrin-releasing peptide (GRP) is a mammalian counterpart of the amphibian peptide bombesin (BB) that stimulates cell proliferation, acts as a growth factor in the pathogenesis of many types of cancer, and regulates several aspects of neuroendocrine function. BB and GRP act by binding to the GRPpreferring type of BB receptor (GRPR, also known as BB2 receptor), a member of the superfamily of G-protein coupled membrane receptors. This review summarizes recent evidence from animal and human studies indicating that abnormalities in GRPR function in the brain might play a role in the pathogenesis of neurological and psychiatric disorders, and suggesting that BB, GRP, and GRPR antagonists might display therapeutic actions in central nervous system diseases.

Keywords:

Bombesin-like peptides, gastrin-releasing peptide, gastrin-releasing peptide receptor, neuropeptides, neurological disorders

Affiliation:

Laboratory of Molecular Neuropharmacology, Department of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, 90050-170 Porto Alegre, RS, Brazil.